No Data
No Data
Needham Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $104
Is It Apt to Retain HAE Stock in Your Portfolio for Now?
Demystifying Haemonetics: Insights From 5 Analyst Reviews
Haemonetics Price Target Lowered to $104 From $108 at Needham
Haemonetics Is Maintained at Buy by Needham
Haemonetics Analyst Ratings